Findings

What do systematic reviews say?

10 questions · 10 findings · 2 reviews · All outcomes

Sort:Best matchNewest Highest certainty Download CSV

No studies found 2 · 20%GRADE not reported 8 · 80%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

Polaprezinc vs Azulene oral rinse

Salivary flow rate · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes
No data on salivary flow rates were reported.
0 studies
No studies found

Polaprezinc vs Azulene oral rinse

Side effects · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes
No data on adverse events were reported.
0 studies
No studies found

Polaprezinc vs Azulene oral rinse

Survival · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region

1 finding from 1 review

Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes
Tumour response by RECIST criteria reported for a specific group of patients only; no usable survival data (Watanabe 2010)
1 study
GRADE not reported

Polaprezinc vs Azulene oral rinse

Taste disturbance (severe, > 2 on 0-3 scale) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region

Polaprezinc led to lower taste disturbance (severe, > 2 on 0-3 scale) compared with azulene oral rinse; GRADE not reported.

1 finding from 1 review

Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes
Over RT period
RR 0.12 [0.02, 0.83]
1 study · 31 participants
GRADE not reported

Polaprezinc vs Azulene oral rinse

Xerostomia (severe) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region

Polaprezinc led to lower xerostomia (severe) compared with azulene oral rinse; GRADE not reported.

1 finding from 1 review

Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes
End of RT
RR 0.17 [0.04, 0.65]
1 study · 31 participants
GRADE not reported

Polaprezinc vs Azulene oral rinse

Oral pain · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region

Polaprezinc led to lower oral pain (severe, > 2 on 0-3 scale) compared with azulene oral rinse; GRADE not reported.

1 finding from 1 review

Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes
Over RT period
RR 0.36 [0.17, 0.77]
1 study · 31 participants
GRADE not reported

Polaprezinc vs Azulene oral rinse

Disability of oral intake · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region

Polaprezinc showed no clear difference in disability of oral intake compared with azulene oral rinse; GRADE not reported.

1 finding from 1 review

Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes
Over RT period
RR 0.31 [0.07, 1.31]
1 study · 31 participants
GRADE not reported

Polaprezinc vs Azulene

Oral mucositis (moderate to severe) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies

Polaprezinc led to lower oral mucositis (moderate to severe) compared with azulene; GRADE not reported.

1 finding from 1 review

Interventions for preventing oral mucositis for patients with cancer receiving treatment 2011 · Cochrane All outcomes
Median 28 days
RR 0.43 [0.22, 0.84]
1 study · 31 participants
GRADE not reported

Polaprezinc vs Azulene

Oral mucositis (any severity) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies

Polaprezinc showed no clear difference in oral mucositis (any severity) compared with azulene; GRADE not reported.

1 finding from 1 review

Interventions for preventing oral mucositis for patients with cancer receiving treatment 2011 · Cochrane All outcomes
Median 28 days
RR 0.82 [0.63, 1.06]
1 study · 31 participants
GRADE not reported

Polaprezinc vs Azulene

Oral mucositis (severe) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies

Polaprezinc led to lower oral mucositis (severe) compared with azulene; GRADE not reported.

1 finding from 1 review

Interventions for preventing oral mucositis for patients with cancer receiving treatment 2011 · Cochrane All outcomes
Median 28 days
RR 0.09 [0.01, 0.65]
1 study · 31 participants
GRADE not reported